• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Pimecrolimus effective first-line treatment for atopic dermatitis

byBrandon ChildsandCordelia Ross
March 23, 2015
in Dermatology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 1. The majority of patients using pimecrolimus cream (PIM, 52.6%) or topical corticosteroids (TCS, 50.5%) for the treatment of mild to moderate atopic dermatitis were cleared of manifestations of the disease by week 3 of use.

2. No significant differences in adverse effects and safety or changes in immunity were seen between the PIM and TCS treatment groups. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Atopic dermatitis (eczema) is a chronic, inflammatory skin disease that affects up to 25% of all infants. TCS are typically used as first-line treatment, but many patients and parents are non-compliant due to fear of their potential side effects. Researchers of the current study sought to compare the safety and efficacy of TCS and PIM in the treatment of mild to moderate atopic dermatitis. PIM is a topical calcineurin inhibitor used as first line therapy for atopic dermatitis in sensitive skin areas. Results showed that a majority of patients in both groups were cleared of the disease by week 3 of treatment. Patients in the PIM group required a much smaller amount of subsequent steroid use for exacerbations and achieved similar results. No significant differences in adverse effects or impairment of humoral or cellular immunity were seen between groups. This study is limited by adverse effect analyses that were not adjusted for the multiplicity of comparisons. Nonetheless, these findings may influence pediatricians to use PIM as a first-line agent in the treatment of atopic dermatitis in patients whose parents may be hesitant to use TCS.

Click to read the study, published today in Pediatrics

Relevant Reading: Atopic dermatitis

In-Depth [randomized controlled trial]: A total of 2439 children, ages 3 to 12 months, with atopic dermatitis were randomized into low potency TCS or PIM treatment arms. Parents were instructed to use the allotted treatment cream until atopic dermatitis had cleared. The medication could be restarted if the disease returned, and the PIM group was told to start a TCS if an exacerbation was not controlled by the assigned treatment. Treatment success was defined as being clear or almost clear of the disease, and success was achieved at week 3 by 52.6% and 50.5% of patients in the PIM and TCS groups, respectively. At the end of the 5-year study period, 88.7% of the PIM group and 92.3% of the TCS group reached overall treatment success. Patients in the PIM group used TCSs for a median of 7 days vs. 178 days in the TCS group. The PIM group experienced significantly more episodes of bronchitis (p = .02), infected eczema (p < .001), impetigo (p = .045), and nasopharyngitis (p = .04). Similar increases in immunoglobulin levels and decreases in peripheral blood T and B lymphocytes at baseline to week 260 were seen in both groups and were considered normal when compared to historical controls.

RELATED REPORTS

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: corticosteroidsEczema
Previous Post

Low-dose gonadotropin ovulation induction superior to clomiphene

Next Post

Collaborative care may improve outcomes in childhood ADHD

RelatedReports

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease
StudyGraphics

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

January 6, 2022
#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation
StudyGraphics

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

December 23, 2021
Adalimumab aids in control of noninfectious uveitis
Infectious Disease

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

October 26, 2021
#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis
StudyGraphics

#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis

August 26, 2021
Next Post
Collaborative care may improve outcomes in childhood ADHD

Collaborative care may improve outcomes in childhood ADHD

Incidental findings common with breast imaging, often benign

2 Minute Medicine Rewind March 16 – March 22, 2015

Further evidence of link between antithyroid drugs in pregnancy and birth defects

Insufficient evidence to recommend screening for thyroid dysfunction in asymptomatic adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.